» Articles » PMID: 31126596

Irreversible Electroporation Versus Radiofrequency Ablation: Comparison of Systemic Immune Responses in Patients with Hepatocellular Carcinoma

Overview
Date 2019 May 26
PMID 31126596
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Irreversible electroporation (IRE) differs from thermal radiofrequency (RF) ablation, especially in terms of the reparative process in the ablation zone induced. To elucidate this, the systemic immune responses after 2 mechanistically different types of ablation (IRE and RF ablation) were evaluated in patients with hepatocellular carcinoma (HCC).

Materials And Methods: Twenty-one patients with HCC who underwent either RF ablation (n = 11) or IRE (n = 10) were studied. Peripheral blood samples were collected from all patients at 4 timepoints: before ablation, within 1 hour after ablation, 1 day after ablation, and 4 days after ablation. The phenotypes and functions of immune cells in peripheral blood and serum levels of cytokines and chemokines were monitored and analyzed using the mixed-effects model. Follow-up radiological images were also obtained to assess temporal changes in the ablation zone.

Results: The most significant difference was seen in the levels of macrophage migration inhibitory factor (MIF) in the IRE group compared to the RF ablation group (P = .0011): the serum levels of MIF in the IRE group significantly increased immediately after IRE and then rapidly decreased to the pre-ablation range 1 day after IRE, but, in contrast, no consistent trend was observed in the RF ablation group. The axial diameter (P = .0009) and area (P = .0192) of the ablation zone of IRE were significantly smaller than those of RF ablation 1 year after ablation.

Conclusions: IRE was found to be associated with a significant early increase in MIF levels, which may facilitate the early reparative process and result in significant shrinkage of the ablation zone.

Citing Articles

Pulsed field ablation in medicine: irreversible electroporation and electropermeabilization theory and applications.

Jacobs E, Rubinsky B, Davalos R Radiol Oncol. 2025; 59(1):1-22.

PMID: 40014783 PMC: 11867574. DOI: 10.2478/raon-2025-0011.


A multicenter, randomized, parallel-controlled clinical trial protocol to evaluate the safety and efficacy of irreversible electroporation compared with radiofrequency ablation for the treatment of small hepatocellular carcinoma.

Cheng C, Xu M, Pan J, Chen Q, Li K, Xu D World J Surg Oncol. 2024; 22(1):332.

PMID: 39707376 PMC: 11662571. DOI: 10.1186/s12957-024-03614-z.


Irreversible Electroporation as a Valid Treatment Option for Hepatic Epithelioid Hemangioendothelioma: An International Multicenter Experience.

Narayanan G, Spano A, Gentile N, Shnayder-Adams M, Gurusamy V, Levi D Cardiovasc Intervent Radiol. 2024; 47(7):883-890.

PMID: 38844684 PMC: 11239779. DOI: 10.1007/s00270-024-03770-5.


Irreversible Electroporation of the Hepatobiliary System: Current Utilization and Future Avenues.

Narayanan G, Koethe Y, Gentile N Medicina (Kaunas). 2024; 60(2).

PMID: 38399539 PMC: 10890312. DOI: 10.3390/medicina60020251.


Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.

Wade R, South E, Anwer S, Sharif-Hurst S, Harden M, Fulbright H Health Technol Assess. 2023; 27(29):1-172.

PMID: 38149643 PMC: 11017143. DOI: 10.3310/GK5221.